AVB-101: A Promising Treatment for Frontotemporal Dementia with Progranulin Mutations

What is AVB-101?

AVB-101, also known as AVB.PGRN, is an innovative medical treatment currently being studied for patients with a specific type of frontotemporal dementia1. It is classified as a gene therapy product, which means it uses genetic material to treat a disease2.

Specifically, AVB-101 is a recombinant AAV-9 vector expressing the human progranulin protein. In simpler terms, it's a specially designed virus that carries genetic instructions to produce a protein called progranulin in the brain3.

Target Condition: Frontotemporal Dementia with Progranulin Mutations (FTD-GRN)

AVB-101 is being developed to treat a condition called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN)4. Let's break this down:

• Frontotemporal Dementia (FTD): This is a type of dementia that affects the frontal and temporal lobes of the brain, which are responsible for personality, behavior, and language5.
• Progranulin Mutations (GRN): Some people with FTD have mutations in the gene that produces progranulin, a protein important for brain health. These mutations lead to a shortage of progranulin6.

People with FTD-GRN typically experience changes in personality, behavior, and language skills. The disease is inherited and usually starts affecting people between the ages of 30 and 757.

How AVB-101 Works

AVB-101 aims to address the root cause of FTD-GRN by providing the brain with the genetic instructions to produce progranulin8. Here's how it works:

1. The treatment uses a harmless virus (AAV-9) as a carrier for the healthy progranulin gene.
2. This virus is injected into specific areas of the brain.
3. The virus delivers the healthy gene to brain cells.
4. The brain cells then use this gene to produce the missing progranulin protein.

By increasing progranulin levels in the brain, researchers hope to slow down or potentially stop the progression of FTD-GRN9.

Administration of AVB-101

AVB-101 is administered through a procedure called bilateral intrathalamic infusion. This means:

• Bilateral: The treatment is given to both sides of the brain.
• Intrathalamic: It's injected into a specific part of the brain called the thalamus.
• Infusion: The medication is slowly introduced into the brain tissue10.

This is a surgical procedure that requires general anesthesia and is performed by specialized neurosurgeons11.

Clinical Trial Details

AVB-101 is currently being studied in a Phase 1/2 clinical trial. Here are some key points about the study:

• It's an open-label study, which means both the researchers and participants know which treatment is being given.
• The study uses ascending doses, meaning they start with a low dose and gradually increase it to find the best balance of effectiveness and safety.
• The main goal is to evaluate the safety and tolerability of AVB-101.
• The study also aims to get preliminary data on how well AVB-101 works12.

Eligibility Criteria

Not everyone with FTD-GRN can participate in this study. Some key eligibility criteria include:

• Age between 30 and 75 years
• Confirmed genetic mutation in the progranulin (GRN) gene
• Diagnosis of frontotemporal dementia
• Certain scores on cognitive tests
• Adequate brain structure as seen on MRI scans13

There are also several exclusion criteria, such as severe dementia, certain medical conditions, or previous gene therapy treatments14.

Safety and Efficacy Measures

The study will closely monitor participants for safety and signs that the treatment is working. Some of the key measures include:

• Adverse events and side effects
• Changes in cognitive function
• Brain imaging results
• Levels of progranulin in the cerebrospinal fluid and blood
• Levels of neurofilament light chain (NfL), a marker of brain cell damage
• Changes in clinical dementia rating scales15

Participants will be followed for up to 5 years to assess long-term safety and effectiveness16.